As 5-aza-2’-deoxycytidine treatment induces cell cycle arrest in MDS cells, TWIST1 driven loss of cell cycle inhibition and reduced G0/G1 arrest may contribute to an enhanced resistance to 5-aza-2’-deoxycytidine treatment upon TWIST1 expression. The gene discussed is TWIST1; the disease is myelodysplastic syndrome.